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Abstract
Background: A sensitive assay to identify biomarkers using non-invasively collected clinical specimens is ideal for breast
cancer detection. While there are other studies showing disease biomarkers in saliva for breast cancer, our study tests the
hypothesis that there are breast cancer discriminatory biomarkers in saliva using de novo discovery and validation
approaches. This is the first study of this kind and no other study has engaged a de novo biomarker discovery approach in
saliva for breast cancer detection. In this study, a case-control discovery and independent preclinical validations were
conducted to evaluate the performance and translational utilities of salivary transcriptomic and proteomic biomarkers for
breast cancer detection.
Methodology/Principal Findings: Salivary transcriptomes and proteomes of 10 breast cancer patients and 10 matched
controls were profiled using Affymetrix HG-U133-Plus-2.0 Array and two-dimensional difference gel electrophoresis (2D-
DIGE), respectively. Preclinical validations were performed to evaluate the discovered biomarkers in an independent sample
cohort of 30 breast cancer patients and 63 controls using RT-qPCR (transcriptomic biomarkers) and quantitative protein
immunoblot (proteomic biomarkers). Transcriptomic and proteomic profiling revealed significant variations in salivary
molecular biomarkers between breast cancer patients and matched controls. Eight mRNA biomarkers and one protein
biomarker, which were not affected by the confounding factors, were pre-validated, yielding an accuracy of 92% (83%
sensitive, 97% specific) on the preclinical validation sample set.
Conclusions: Our findings support that transcriptomic and proteomic signatures in saliva can serve as biomarkers for the
non-invasive detection of breast cancer. The salivary biomarkers possess discriminatory power for the detection of breast
cancer, with high specificity and sensitivity, which paves the way for prediction model validation study followed by pivotal
clinical validation.
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Introduction
Early detection of breast cancer is the key to positive, long-
lasting outcomes, thus reducing the suffering and cost to society
associated with the disease [1]. The high burden of breast cancer
in women worldwide underscores the unmet potential of
biomarker for early detection. A significant obstacle towards early
detection of breast cancer is the development of methods that
efficiently and accurately identify potentially affected individuals
[2,3].
Breast cancer has been among the earliest and most intensely-
studied diseases using gene expression profiling and protein
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reveal the biological spectrum of breast cancers, providing
diagnostic tools as well as prognostic and predictive gene
signatures [4,5]. Breast cancer detection is currently based on
physical examination and imaging (mammography, ultrasound,
and MRI) [6], although emerging methods include direct
examination of the cytomorphology of exfoliated cells [7], and
the molecular analysis of tumor biomarkers in nipple aspirate
fluid or in ductal lavage [8,9,10]. In the last decade, biomarker
discoveries for breast cancer detection have focused on blood
and/or tissue, using proteomic [11,12,13,14,15,16], transcrip-
tomic [17,18,19,20,21], and genomic approaches [22,23]. In
comparison to prognostic biomarkers [24,25,26], the develop-
ment of detection biomarkers has been limited, mainly due to a
lack of sensitivity and specificity for this clinical context [2,27,28].
Most importantly, the use of tissue biomarkers for early detection
will be limited to patients at very high risk because they rely on
invasive procedures.
Recently, the study of salivary biomarkers has developed
beyond oral diseases [29,30,31,32] to systemic diseases [33,34],
broadening the potential for systemic disease detection
[35,36,37,38,39]. Saliva-based translational research and tech-
nology is now at a mature juncture and can be evaluated to
determine its utility for breast cancer detection. Explorative
studies have evaluated the potential use of salivary proteins such
as c-erbB-2, VEGF, EGF, and CEA in the initial detection and/
or follow-up screening for the recurrence of breast cancer
[33,40,41,42,43,44]. However, these investigations were not
based on biomarker discoveries from saliva specimens, rather
they were testing blood biomarkers in saliva [45]. Here, we
report the use of transcriptomic and proteomic approaches to
discover and pre-validate biomarkers in saliva for the non-
invasive detection of breast cancer. Our results demonstrate
significant differences in salivary transcriptomic and proteomic
profiles between breast cancer patients and controls. The
discovered salivary biomarkers possess discriminatory power
for the detection of breast cancer, with high specificity and
sensitivity.
Results
Variation of salivary gene expression profiles and
identification of mRNA biomarkers
Schematic of the study design and demographic information of
all subjects used for the discovery and pre-validation phases are
shown in Figure 1 and Table 1, respectively. Transcriptomic
profiling identified 1402 genes exhibiting .2 fold up-regulation,
and 2247 genes exhibiting .2 fold down-regulation, in the saliva
of breast cancer patients, relative to the matched controls (n=20,
P,0.05). These transcriptomic changes were unlikely to be due to
chance alone (x
2 test, P,0.0001), considering the false positive rate
with P,0.05. Using a predefined criterion of a change in
regulation .2-fold, and a more stringent cutoff of P,0.01, 358
up-regulated and 943 down-regulated transcripts were identified
in the saliva of breast cancer samples. RT-qPCR was performed to
verify the microarray results on the discovery sample set (n=20).
The top 27 up-regulated candidates (Table S1) were selected based
on p-value and fold-change (P,0.01, and .10-fold). The RT-
qPCR results confirmed that the relative RNA expression levels of
11 up-regulated transcripts were consistent with the microarray.
These verified transcriptomic biomarker candidates were then
subjected to independent pre-validation by RT-qPCR using a
cohort of 30 breast cancer patients and 63 controls (Figure 1).
Eight up-regulated genes were pre-validated, showing significant
differences between breast cancer and healthy controls (n=93,
Table 2).
Variation of salivary proteomic profiles and identification
of protein biomarkers
Proteomic profiling by 2D-DIGE revealed 35 up-regulated
proteins/spots and 32 down-regulated proteins/spots in the saliva
of breast cancer patients, relative to the matched controls (n=20).
Twenty spots, 14 up-regulated (.1.5 fold) and 6 down-regulated
(.1.5 fold), were selected for protein identification, resulting in the
identification of 10 up-regulated and 4 down-regulated proteins
(Table S1). Four proteins (carbonic anhydrase VI (CA6), psoriasin,
transthyretin, and cyclophilin A) with available antibodies were
Figure 1. Schematic of the study design following the STARD reporting guideline.
doi:10.1371/journal.pone.0015573.g001
Salivary Biomarkers Detect Breast Cancer
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15573subjected to verification using immunoblot on the discovery
sample set. The levels of CA6 and psoriasin between cancer and
control samples showed significant differences (p=0.012 and
0.014, respectively). These verified proteomic biomarker candi-
dates were then independently validated by protein immunoblot-
ting using the pre-validation cohort (30 breast cancer patients
versus 63 controls). The level of CA6 showed a significant
difference between breast cancer and healthy controls (n=93,
Table 2).
Evaluation of the validated transcriptomic and proteomic
biomarkers
Using logistic regression, the accuracy, sensitivity and specificity
of 9-validated-biomarker combination on the pre-validation
sample set (n=93) were 92% (86 of 93), 83% (25 of 30) and
97% (61 of 63), respectively (Figure 2A). Principle component
analysis (PCA) of this 9-biomarker combination could separate the
breast cancer patients from the controls along the first principal
component (t-test, P-value=2.7E-15) (Figure 2B). None of the
confounding factors (age, ethnicity, smoking status, menopausal
status, and HRT treatment) significantly affected the validated
biomarkers (Table 2). These indicate that cancer onset is a major
source of variation in the expression of the validated biomarker.
Furthermore, cross-disease comparisons showed that none of the
validated mRNA biomarkers’ expression was significantly altered
in other salivary transcriptomic profiling studies, indicating their
specificity for breast cancer detection (Table 3).
Discussion
Early detection of breast cancer offers the promise of easier
treatment (smaller surgeries, less radiation or chemotherapy) and
improved survival. Conventional screening (physical examination and
mammography) has a less-than-desirable sensitivity and specificity [6].
There is a soaring need for new therapeutic strategies, as well as
biomarkers that can achieve effective non-invasive early detection of
Table 1. Demographic Information of All Subjects Used for the Discovery and Pre-validation Phases.
Demographic
Variable Characteristics Discovery Phase Pre-validation Phase
Breast Cancer
(n=10)
Healthy Control
(n=10) p-value Breast Cancer (n=30)
Healthy Control
(n=63) p-value
Age (y) Mean 6 SD 52.25610.44 51.6610.31 0.89 52.74612.11 52.52612.16 0.66
Gender Female 10 10 30 63
Ethnicity Caucasian 5 (50%) 8 (80%) 0.44 19 (64.5%) 53 (83.9%) 0.07
African-American 2 (20%) 0 1 (3.2%) 4 (6.5%)
Asian 0 0 6 (19.4%) 4 (6.5%)
Hispanic 3 (30%) 2 (20%) 0 1 (1.6%)
Other 4 (12.9%) 1 (1.6%)
Smoking 3 3 10 (33.3%) 24 (38.1%) 1
HRT 10 (33.3%)
Menopausal status Pre 5 5 12 (40%) 32 (50.8%) 0.37
Post 5 5 18 (60%) 31 (49.2%)
doi:10.1371/journal.pone.0015573.t001
Table 2. Validated biomarkers for breast cancer detection and effect of confounding factors (Pre-validation sample set n=93).
Biomarker P-value cv.err Age Ethnicity
Menopausal
Status
Smoking
Status HRT
Reported Relation to Breast
Cancer or Other Cancers
CSTA 4.19E-13 0.333 0.16 0.78 0.24 0.95 0.08 [50]
TPT1 5.38E-05 0.251 0.30 0.60 0.13 0.87 0.17 [51]
IGF2BP1 2.57E-04 0.312 0.78 0.90 0.41 0.89 0.42 [52]
GRM1 6.57E-03 0.262 0.42 0.71 0.18 0.89 0.23 [53]
GRIK1 3.24E-02 0.237 0.70 0.80 0.36 0.88 0.20 [54]
H6PD 1.46E-03 0.262 0.57 0.73 0.30 0.76 0.21 [55]
MDM4 7.30E-04 0.297 0.55 0.79 0.27 0.89 0.25 [56]
S100A8 1.96E-03 0.272 0.54 0.86 0.31 0.88 0.22 [57]
CA6 1.70E-03 0.427 0.76 0.21 0.51 0.81 1.00 [58,59]
NOTE: Eight mRNA biomarkers (in italic) were validated by RT-qPCR and one protein biomarker was validated by immunobloting using the validation sample set,
including saliva from 30 breast cancer patients and 63 healthy control subjects. The Mann-Whitney rank sum test was used to determine marker validation. Possible
confounding factors, including age, ethnicity, smoking status, menopausal status, and HRT treatment, were evaluated on the validated biomarkers by logistic regression
model. Linear regression model was constructed for each marker and used the factors cancer/normal and one of the confounders. Abbreviations: cv.err: cross validation
error rate.
doi:10.1371/journal.pone.0015573.t002
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invasive tool for the early detection of breast cancer. We envision a
clinical context in which a salivary test may enable clinicians to detect
breast cancer earlier (by identifying patients warranting closer follow-
up and additional imaging), and reduce the number of unnecessary
biopsies (currently about 80% according to the American Cancer
Society), in a cost-effective manner. The purpose of this study, which is
an essential step toward attaining our long-range goal, is to evaluate
the potential utility of salivary transcriptomes and proteomes for breast
cancer detection. We applied two high-throughput technologies in
order to assess 1) whether the salivary transcriptome and proteome
profiles change with the onset of breast cancer, and 2) whether
discriminatory biomarkers can be identified and validated. By
addressing both questions, our profiling results, and further
independent validation of the discovered biomarkers, will open new
research directions and support the idea that saliva is a useful
biomarker source for breast cancer detection.
The salivary transcriptomeis a novel diagnostic alphabetwe have
explored for discovering breast cancer biomarkers. Salivary
transcriptional profiling technology has been successfully applied
for discovering detection biomarkers of resectable pancreatic cancer
[34]. Consistent with that study, high-throughput profiling revealed
significant variations in gene signature profiles between the breast
cancer patients and the controls, demonstrating that the salivary
transcriptome is an informative biomarker source for systemic
cancer detection. The gene ontology analysis could categorize the
1301 up/down-regulated genes (.2 fold up/down-regulation,
P,0.01) into various biological processes based on their known
roles or functions. The 1301 genes were enriched in functions
related to metabolic processes (35.46%), biological regulation
(30.31%), and regulation of biological process (28.24%) (Figure
S1). Based on the microarray data of 358 up-regulated transcripts
(.2-fold change, P,0.01), breast cancer patients (n=10) and
matched controls (n=10) could be classified into two distinct groups
Figure 2. Clinical utility of the validated biomarkers. A, Combination of nine validated biomarkers achieved a sensitivity of 83% (25 of 30
cancer subjects) with only a 3% false-positive rate (2 of the 63 control subjects). The shading of the contingency table boxes reflects the fraction of
each samples type in each quadrant. ‘Cancer’ and ‘Non’ headings indicate subjects with and without cancer, respectively. SB+ and SB2, salivary
biomarker test positive or negative, respectively; NPV, negative predictive value; PPV, positive predictive value; Sen, sensitivity; Spec, specificity.
B, Score plot of principle component analysis (PCA). Combining the nine validated biomarkers, the control subjects (green dots) separate from breast
cancer patients (red dots), with cumulative proportions of 66.9% for PC1 and 21.6% for PC2.
doi:10.1371/journal.pone.0015573.g002
Table 3. Cross-disease comparisons of 8 validated salivary mRNA biomarkers.
Biomarker Oral cancer Lung cancer Pancreatic cancer Ovarian cancer Diabetes pSS Breast cancer
S100A8 0.341 0.246 0.704 0.049 0.700 0.798 ,0.001 *
CSTA 0.341 0.029 0.197 0.678 0.648 0.750 ,0.001 *
GRM1 0.341 0.242 0.126 0.523 0.419 0.061 0.001 *
TPT1 0.341 0.112 0.558 0.090 0.454 0.855 ,0.001 *
GRIK1 0.341 0.589 0.543 0.489 0.948 0.629 0.006 *
H6PD 0.343 0.517 0.475 0.293 0.330 0.101 ,0.001 *
IGF2BP1 0.341 0.102 0.316 0.275 0.697 0.820 0.002 *
MDM4 0.341 0.011 0.154 0.455 0.088 0.168 0.001 *
NOTE: All analysis and comparison were based on microarray data. The validated mRNA biomarkers for breast cancer detection were checked against other microarray
datasets (see text). Briefly, t-test p-values were calculated for all breast-cancer-validated genes in the other microarray datasets to check for significant variation (* after
Bonferonni correction, P,0.006) between patients and controls in those diseases. Sample sizes of these microarray studies were 10 vs. 10 for oral cancer, 10 vs. 10 for
lung cancer, 12 vs. 12 for pancreatic cancer, 11 vs. 11 for ovarian cancer, 13 vs. 13 for diabetes, 8 vs. 10 for pSS, and 10 vs. 10 for breast cancer.
doi:10.1371/journal.pone.0015573.t003
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of salivary mRNA biomarkers (Figure S2). Our aim with
transcriptomic profiling is not to identify large numbers of
differentially expressed genes; rather we seek to find a small number
of truly differentially expressed genes that can be validated. In this
study, eight out of 27 top up-regulated transcripts (P,0.01, and
.10-fold) were pre-validated using an independent cohort, yielding
a validation rate of 29.6%that is similar to one ofour previousstudy
for pancreatic cancer (validation rate, 24.5%) [34].
Proteomic profiling, without independent validation, has been
recently performed for discovering salivary biomarkers using
stimulated whole saliva [46]. The results of our proteomic study
overlap little with this previous proteomic profiling. This
discrepancy could be due to the use of different disease types
(invasive ductal carcinomas (IDC) versus ductal carcinoma in situ
(DCIS)), different sample materials (unstimulated versus stimulated
saliva), and different technical platforms. More importantly, we
have conducted a pre–validation of the discovered protein
biomarkers using an independent sample set. Interestingly, CA6,
which was validated in our study, was also discovered in this
previous proteomic profiling study using saliva samples from non-
invasive breast cancer patients (DCIS) [46], indicating the
potential of this biomarker for the early detection of breast cancer.
In order to obtain a more realistic estimate of the clinical utility
of the validated biomarkers, and avoid the consequences of
potential data overfitting, we employed leave-one-out cross-
validation. The cross validation rate (cv.err) reflects a more
accurate estimate of the true prediction accuracy of the biomarker.
Except CA6, all comparisons have cross validation rates of
#0.333, indicating that the validated biomarkers in general have
high prediction accuracy (Table 2). Despite our moderate sample
size, we appear to have identified biomarkers that significantly
correlate with the presence of breast cancer.
Although the underlying relationships among systemic diseases
and the saliva biomarkers are unclear, our recent study using mouse
models has indicated that upon systemic disease development,
cancer-specific changes occur in the salivary transcriptomic profiles
[38]. Stimulation of the salivary glands by mediators released from
remote tumors plays an important role in regulating the salivary
surrogate biomarker profiles [38]. There may be extracellular
communication between the ductal tissues of the breast and those of
the salivary glands, since the histophysiology is very similar between
these two distant tissues [46]. Interestingly, all validated biomarkers
were previously implicated in breast cancer or other cancers
(Table 2). Further investigation into the mechanism of salivary
biomarkers for systemic cancers is warranted.
In summary, our study has identified transcriptomic and
proteomic biomarkers in saliva that have the potential to impact
current diagnostic triage for breast cancer. The salivary biomark-
ers’ discriminatory power paves the way for a PRoBE-designed
definitive validation study [45]. The critical feature of PRoBE
design involves prospective clinical sample collection, before
outcome ascertainment, from a study cohort that is relevant to
the clinical application [45]. Any biomarker test intended for FDA
approval and clinical use should incorporate the PRoBE principles
as early as possible, as these principles eliminate potential biases
commonly seen at the discovery stage.
Materials and Methods
Subject information and study design
This study, which was approved by the UCLA and Cedars-
Sinai Medical Center Institutional Review Boards (#06-07-043
and #3870, respectively), began sample collection in February
2007. Written informed consents and questionnaire data sheets
were obtained from all patients who agreed to serve as saliva
donors. The saliva bank for breast cancer project at the UCLA
Dental Research Institute, in collaboration with the Cedars-Sinai
Medical Center, has collected 178 saliva samples from subjects
recruited from the Saul and Joyce Brandman Breast Cancer
Center. Of these, 113 samples, including 40 breast cancer patients
and 73 healthy control individuals (Table 1), were used for the
discovery and pre-validation phases of this study. Inclusion criteria
of cancer patients consisted of a confirmed diagnosis of breast
cancer. Exclusion criteria of cancer patients included therapy/
surgery and/or a diagnosis of other malignancies within 5 years
prior to saliva collection. Exclusion criteria of control patients
included a diagnosis of any malignancies within 5 years prior to
saliva collection (Figure 1). The information on patient character-
istics, such as age, ethnicity, smoking history, menopausal status,
and hormone replacement therapy (HRT), is presented in Table 1.
Unstimulated saliva samples were consistently collected, stabilized,
and preserved as previously described [34] (Figure S3). The
sample supernatants were reserved at 280uC prior to assay.
This study consisted of a discovery phase, followed by an
independent preclinical validation phase. Of the 113 samples, 10
breast cancer samples and 10 matched control samples were used
for the discovery phase. All breast cancer cases were invasive
ductal carcinoma (IDC), the most common type of breast cancer.
Biomarkers identified from the discovery studies were first verified
using the discovery sample set. An independent sample set,
including 30 breast cancer patients and 63 controls, was used for
the biomarker pre-validation phase (Figure 1).
Salivary transcriptomic profiling and data analysis
RNA was isolated from 330 ml of saliva supernatant using
MagMax
TM Viral RNA Isolation Kit (Ambion, Austin, TX). This
process was automated using KingFisher mL technology (Thermo
Fisher Scientific, Waltham, MA), followed by TURBO
TM DNase
treatment (Ambion, Austin, TX). Extracted RNA was linearly
amplified using the RiboAmp RNA Amplification kit (Molecular
Devices, Sunnyvale, CA). After purification, cDNA was tran-
scribed and biotinylated using GeneChip Expression 39-Amplifi-
cation Reagents for in vitro transcription labeling (Affymetrix,
Santa Clara, CA). Chip hybridization and scanning were
performed at the UCLA microarray core facility. Using the
MIAME criteria [47], all Affymetrix Human Genome U133 Plus
2.0 Array data generated in this study were uploaded to the GEO
database [48], accession number GSE20266.
The analysis was performed using R 2.7.0 with samr and ROC
packages [49]. The Probe Logarithmic Intensity Error Estimation
(PLIER) expression measures were computed after background
correction and quantile normalization for each microarray dataset.
Probeset-level quantile normalization was performed across all
samples to make the effect sizes similar among all datasets. Finally,
for every probeset, significance analysis of microarray (SAM) was
applied to identify differential expression between the cancer and
healthy control samples. The probesets were then ranked by the
false discovery rate (FDR) corrected p-values.
Preclinical validation of mRNA biomarkers using reverse
transcription quantitative PCR (RT-qPCR)
The identified mRNA biomarkers were first verified by RT-
qPCR using the discovery sample set (10 cancer versus 10 controls)
as described previously [34]. RT-qPCR primers were designed
using Primer Express 3.0 software (Applied Biosystems, Foster City,
CA) (Table S2). All primers were synthesized by Sigma-Genosys
(Woodlands, TX), and the amplicons were intron spanning
Salivary Biomarkers Detect Breast Cancer
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biomarkers were then assayed by RT-qPCR in the set of 93
independent samples (30 breast cancer patients versus 63 controls).
Raw data were normalized by subtracting GAPDH Ct values from
the biomarker Ct values to generate DCt. The Mann-Whitney rank
sum test was used for between-group biomarker comparisons.
Salivary proteomic profiling and data analysis
Two-dimensional difference gel electrophoresis (2D-DIGE) was
performed by Applied Biomics (Hayward, CA). Briefly, by taking
equal amounts of protein from each sample, 10 cancer samples and
10 control samples were pooled separately, with each pool
containing 250 mg of proteins. The proteins in each pool were
precipitated by methanol and labeled with Cy3 and Cy5,
respectively, and then combined for 2D-DIGE. After loading the
labeled samples, the isoelectric focusing (IEF, pH 3–10) was run
following the protocol provided by Amersham BioSciences (Piscat-
away, NJ). The immobilized pH gradient (IPG) strips were rinsed in
the SDS-gel running buffer before transferring onto 13.5% SDS
gels. The fold change of the protein expression levels was obtained
from in-gel DeCyder analysis (Amersham BioSciences).Spots with a
fold-change larger than 1.5 on the gel were subjected to in-gel
trypsin digestion. The digested tryptic peptides were then mixed
with CHCA matrix (alpha-cyano-4-hydroxycinnamic acid) and
spotted into wells of a MALDI plate for MALDI-TOF MS
identification (ABI4800, Applied Biosystems, Foster City, CA).
Preclinical validation of protein biomarkers by
immunoblotting
Protein immunoblotting was used to verify and validate the
proteomic biomarker candidates. Reduced protein samples (15 mg
total protein per lane) were loaded onto a 10% Bis-Tris gel and
run at 150 Volt for one hour. Pre-stained protein standard
(Invitrogen, USA) was used to track protein migration. The
proteins were transferred to a nitrocellulose membrane and
blocked for one hour in 5% non-fat dry milk. After further washes
in TBST wash buffer, the membrane was incubated with the
primary antibody (Lifespan bioscience, Seattle, WA) at room
temperature for two hours. The membrane was then washed in
TBST wash buffer before applying the secondary antibody (Anti-
mouse IgG, peroxidase-linked species-specific whole antibody
from sheep, GE healthcare, Piscataway, NJ) for one hour at room
temperature. Finally, the membrane was washed in TBST wash
buffer and visualized using the ECL Plus detection kit (GE
Healthcare, Piscataway, NJ). The signal intensity of the bands was
measured using Image J software (NIH, Bethesda, MD, USA).
The intensity of a band representing the protein of interest was
divided by the intensity of its corresponding b-actin expression on
the same blot for normalization.
Statistical analysis
Leave-one-out cross-validation was applied to assess the true
accuracy of the model. In this procedure, each observation is
iteratively taken out and the model is trained using all other
observations. A prediction is then made on the left-out
observation. The overall accuracy rate for each model is then
the proportion of left out observations that are correctly predicted.
To evaluate possible confounders for the markers versus cancer
relationship, we examined factors such as age, ethnicity, smoking
status, menopausal status, and HRT treatment. Linear regression
model was constructed for each marker and used the factors
cancer/normal and one of the above confounders.
The pre-validated breast cancer mRNA biomarkers were checked
in other microarray studies that have been conducted in our
laboratory on different diseases, including oral cancer [31], primary
Sjo ¨gren’s Syndrome (pSS) [30], pancreatic cancer [34], lung cancer,
ovarian cancer, and type 2 diabetes. Briefly, P-value derived from
Wilcoxon rank sum test were calculated for all breast-cancer-study-
validated genes in other microarray datasets to check whether
significant variation between breast cancer and controls also
appeared in those disease datasets. After Bonferonni correction,
variation was considered significant with p-values less than 0.006.
Supporting Information
Figure S1 Gene ontology analysis of the up/down-regulat-
edgenes(1301 genes,.2fold up/down-regulation, P,0.01).
(PDF)
Figure S2 Heatmap of 358 up-regulated transcripts
based on microarray data (.2-fold change, P,0.01).
Hierarchical clustering and gene function enrichment was
performed using Euclidean distance metric and Average linkage
method (unsupervised clustering). Breast cancer patients (n=10)
and healthy controls (n=10) could be classified into distinct
groups, indicating the discriminatory power of salivary mRNA
biomarkers. The GEO database access number of all microarray
experiments is GSE20266.
(PDF)
Figure S3 Protocol for saliva collection.
(PDF)
Table S1 Biomarker candidates selected from tran-
scriptomic and proteomic profiling.
(PDF)
Table S2 Primers of 11 verified transcripts and GAPDH.
(PDF)
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